Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745792 | 0.94 | BCHE (0.40) | BCHELMNAKDM4EALDH1A1MAPT | |
| SCHEMBL4746310 | 0.92 | BCHE (0.34) | BCHELMNAKDM4EALDH1A1MAPT | |
| SCHEMBL4746317 | 0.91 | DHODH (0.35) | BCHELMNAKDM4EALDH1A1MAPT | |
| SCHEMBL4746312 | 0.90 | BCHE (0.34) | BCHELMNAKDM4EALDH1A1MAPT | |
| SCHEMBL4746339 | 0.90 | DHODH (0.36) | BCHELMNAKDM4EALDH1A1MAPT | |
| SCHEMBL4745791 | 0.89 | BCHE (0.37) | BCHELMNAKDM4EALDH1A1MAPT | |
| SCHEMBL4745985 | 0.86 | BCHE (0.33) | BCHEALDH1A1TOP2A | |
| SCHEMBL4746461 | 0.86 | TOP2A (0.33) | BCHEKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL4746409 | 0.86 | PDK2 (0.33) | BCHEKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL4746389 | 0.86 | DHODH (0.34) | BCHELMNAKDM4EALDH1A1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173275-B2 | Azaindenochrysene derivative and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173275-B2 | Azaindenochrysene derivative and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | NR2E3, OR51E2, AZI2 | BCHE 376/4885LMNA 4667/4885KDM4E 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.